CancerTYPE ID

There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about CancerTYPE ID, use the form below and your opinion, advice or comment will appear in this space.

Contact Us | CancerTYPE ID

(844) 319-8111. patientadvocates@biotheranostics.com. CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and...

CancerTYPE ID | Billing Information Sheet for HCPs

Medicare covers CancerTYPE ID® at a predetermined rate with no fees charged to the patient if coverage criteria is met under the Local Coverage Determination To discuss our Patient Assistance Program and eligibility requirements, contact our Patient Advocate Team at 1(844) 319-8111.

CancerTYPE ID | A Widely Adopted Molecular Test for Metastatic...

CancerTYPE ID is a molecular test that provides actionable genomic information for accurate diagnosis for metastatic patients with diagnostic ambiguity. CancerTYPE ID: Mechanism of Action. The Most Important Aspect to Treating Tumors. ^ NeoTYPE Cancer Profiles are performed and billed separately...

News and Press | Breast Cancer Index | About CancerTYPE ID

CancerTYPE ID is the market-leading molecular, gene expression-based test focused on the classification of metastatic cancer and is intended to aid in the diagnosis of the tumor type and subtype of cancers with diagnostic uncertainty, in conjunction with standard clinical and pathological...

PDF Billing information sheet for patients

For specific billing questions, please call Biotheranostics' Reimbursement Department at 1(855) 682-9279. To discuss our Patient Assistance Program and eligibility requirements, contact our Patient Advocate Team at 1(844) 319-8111. *Medicare accepts Breast Cancer Index and CancerTYPE ID as...

CancerTYPE ID® and NeoTYPE® Cancer Profiles | NeoGenomics

CancerTYPE ID followed by NeoTYPE Cancer Profile provides molecular classification of unknown or unclear tumor types and profiling for actionable CancerTYPE ID®. Now also available through NeoGenomics - for unclear or unknown diagnoses in solid tumors. Performed and billed separately by...

CancerTYPE ID

Citation. HAYES, Inc.. CancerTYPE ID.

PMO: Clinical Validation of CancerTYPE ID - YouTube

Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility.

THEROS CANCERTYPE ID Trademark - Registration Number...

THEROS CANCERTYPE ID is a trademark of bioTheranostics, Inc.. Filed in December 23 (2008), the THEROS CANCERTYPE ID covers Scientific research services for medical use in the field of diagnosis and treatment THEROS CANCERTYPE ID - Trademark Details. Status: 710 - Cancelled - Section 8.

Biotheranostics appoints F. Anthony Greco, M.D. as Medical Advisor...

Biotheranostics, Inc., announces F. Anthony Greco, MD as Medical Advisor for its CancerTYPE ID® test. Specializing in cancers of unknown primary, lung cancers, and germ line cancers, Dr. Greco has over 40 years of experience with these challenging cases, both in research and clinical practice...